Redhill Biopharma Ltd Total Liabilities
Redhill Biopharma Ltd total liabilities. Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has total liabilities worth $21.08 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Redhill Biopharma Ltd (RDHL) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Redhill Biopharma Ltd (2010–2025)
Total liabilities of Redhill Biopharma Ltd from 2010 to 2025. This chart illustrates how Redhill Biopharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Redhill Biopharma Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Redhill Biopharma Ltd Competitors by Total Liabilities
The table below lists competitors of Redhill Biopharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nigbas Nigde Beton Sanayi ve Ticaret AS
IS:NIBAS
|
Turkey | TL161.14 Million |
|
Cumulus Media Inc Class A
NASDAQ:CMLS
|
USA | $1.11 Billion |
|
Banzai International Inc
NASDAQ:BNZI
|
USA | $23.38 Million |
|
Icon Energy Corp.
NASDAQ:ICON
|
USA | $37.37 Million |
|
Bioleaders Corporation
KQ:142760
|
Korea | ₩8.29 Billion |
|
Klondike Silver Corp
V:KS
|
Canada | CA$5.39 Million |
|
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
|
USA | $25.77 Million |
|
TRU PRECIOUS METALS CORP.
F:706
|
Germany | €1.95 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Redhill Biopharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Redhill Biopharma Ltd (RDHL) total assets.
Liquidity & Leverage Metrics
Redhill Biopharma Ltd Total Liabilities Ratios Explained
Redhill Biopharma Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Redhill Biopharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Redhill Biopharma Ltd (2010–2025)
The table below shows the annual total liabilities of Redhill Biopharma Ltd from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.08 Million | -7.26% |
| 2024-12-31 | $22.73 Million | +8.33% |
| 2023-12-31 | $20.98 Million | -89.88% |
| 2022-12-31 | $207.27 Million | +20.29% |
| 2021-12-31 | $172.31 Million | +3.57% |
| 2020-12-31 | $166.38 Million | +1080.23% |
| 2019-12-31 | $14.10 Million | +25.59% |
| 2018-12-31 | $11.22 Million | -8.58% |
| 2017-12-31 | $12.28 Million | +6.66% |
| 2016-12-31 | $11.51 Million | +70.51% |
| 2015-12-31 | $6.75 Million | +75.58% |
| 2014-12-31 | $3.85 Million | +59.21% |
| 2013-12-31 | $2.42 Million | +124.03% |
| 2012-12-31 | $1.08 Million | -22.94% |
| 2011-12-31 | $1.40 Million | -88.44% |
| 2010-12-31 | $12.10 Million | -- |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more